What’s driving men to get penis fillers, despite the risks?
Men who have had the procedure can expect 10-20% more girth for the next six to nine months – but it can go wrong.
another news portal
Men who have had the procedure can expect 10-20% more girth for the next six to nine months – but it can go wrong.
Hot weather during the summer can affect anyone, but some people run a greater risk of serious harm.
Dogs who are given supplements containing cannabidiol, or CBD, over a period of years show lowered aggression levels, a new study claims.
A 40-year-old woman in Jefferson County, Pennsylvania has died of complications from measles, according to the county’s coroner. It marks the third vaccine-preventable, measles-linked death
Welcome to Edition 9.10 of the Rocket Report! This week we’re celebrating a historic moment in Europe when a German rocket company successfully put its
The debate over the safety of artificial intelligence grew personal as key tech leaders said calls for government regulation were self-serving and misplaced.
A partial count by Sweden’s election authority projected that left-wing opposition bloc would win a three-seat majority.
Gut microbes need something to eat, and when fiber is limited, they may begin consuming proteins from the mucus lining that protects the gut. Researchers
President Tweety McTreason stunned reporters Sunday after he was asked about his personal use of artificial intelligence. Trump spoke with the press during his flight
A multi-billion-dollar federal program that helps schools and libraries afford broadband internet is under review by the Trump administration, leaving education officials and advocates worried
Most of us carry a phone every day, but very few of us could say what’s actually going on inside one. That gap is exactly
There is no dearth of note taking apps for Linux. There are tools like Obsidian that are local first, tools like Joplin that are both
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung